Reported Earnings • May 31
First quarter 2026 earnings released: kr0.02 loss per share (vs kr0.016 loss in 1Q 2025) First quarter 2026 results: kr0.02 loss per share (further deteriorated from kr0.016 loss in 1Q 2025). Revenue: kr443.0k (up 216% from 1Q 2025). Net loss: kr11.8m (loss widened 13% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Apr 22
Xintela AB (publ), Annual General Meeting, May 22, 2026 Xintela AB (publ), Annual General Meeting, May 22, 2026, at 09:00 W. Europe Standard Time. Location: medicon village (building 601), scheeletorget 1, in lund., lund Sweden Reported Earnings • Mar 02
Full year 2025 earnings released: kr0.07 loss per share (vs kr0.068 loss in FY 2024) Full year 2025 results: kr0.07 loss per share (further deteriorated from kr0.068 loss in FY 2024). Revenue: kr2.28m (down 46% from FY 2024). Net loss: kr48.6m (loss widened 24% from FY 2024). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. New Risk • Jan 23
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr57m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-kr28m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m (kr3.0m revenue, or US$328k). Minor Risk Market cap is less than US$100m (kr263.5m market cap, or US$29.2m). Reported Earnings • Nov 06
Third quarter 2025 earnings released: kr0.01 loss per share (vs kr0.014 loss in 3Q 2024) Third quarter 2025 results: kr0.01 loss per share. Revenue: kr855.0k (down 70% from 3Q 2024). Net loss: kr9.49m (loss widened 22% from 3Q 2024). Reported Earnings • Aug 31
Second quarter 2025 earnings released: kr0.02 loss per share (vs kr0.018 loss in 2Q 2024) Second quarter 2025 results: kr0.02 loss per share (further deteriorated from kr0.018 loss in 2Q 2024). Net loss: kr12.0m (loss widened 20% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • May 23
First quarter 2025 earnings released: kr0.02 loss per share (vs kr0.019 loss in 1Q 2024) First quarter 2025 results: kr0.02 loss per share. Revenue: kr140.0k (down 53% from 1Q 2024). Net loss: kr10.4m (loss narrowed 5.2% from 1Q 2024). Announcement • May 15
Xintela AB (publ), Annual General Meeting, Jun 13, 2025 Xintela AB (publ), Annual General Meeting, Jun 13, 2025, at 09:00 W. Europe Standard Time. Location: at medicon village building 601, scheeletorget 1, lund Sweden Announcement • Apr 15
Xintela AB (publ) Decreases Patient Number in XSTEM Clinical Study in Difficult-To-Heal Leg Ulcers Xintela AB (publ) has amended the study protocol in the clinical phase I/IIa study with XSTEM on patients with difficult-to-heal venous leg ulcers to complete the study earlier. The number of patients to be enrolled in the study has been reduced from 12 to 6. The primary goal of the study, to investigate safety and tolerability, will be achieved even with the reduced number of patients. XSTEM, which consists of allogeneic (donated) integrin a10b1-selected mesenchymal stem cells, is developed and manufactured by Xintela. The Phase I/IIa clinical study in patients with difficult-to- heal venous leg ulcers is a placebo-controlled, randomized study. Patients receive one dose of XSTEM or placebo applied to the wound and are assessed weekly for 10 weeks and after 4 months. The primary goal of the studies is to show safety and tolerability and, also to investigate the preliminary effect of XSTEM in wound healing. The number of patients to been enrolled in the study has been reduce from 12 to 6 due to slow recruitment. To date 5 patients have been dosed of which 4 have completed the study. The amended clinical study protocol has received regulatory approval. New Risk • Mar 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-kr5.9m). Earnings have declined by 0.8% per year over the past 5 years. Revenue is less than US$1m (kr4.2m revenue, or US$420k). Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (kr349.5m market cap, or US$34.8m). Announcement • Mar 18
Xintela AB (publ) Announces Stem Cell Product XSTEM Shows Safety and Positive Efficacy Results in Knee Osteoarthritis Clinical Study Xintela announced interim analysis of data from the knee osteoarthritis clinical study shows safety and positive efficacy results, 18 months after treatment with XSTEM. The results demonstrate statistically significant and clinically meaningful improvements in knee pain and knee function. In addition, the results of XSTEM treatment show an improvement in bone structure and also a trend of stopping cartilage breakdown, supporting a disease-modifying potential of XSTEM in the treatment of osteoarthritis. The highest dose of the three dose levels tested showed the best therapeutic effect. XSTEM, which consists of allogeneic (donated) integrin a10b1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Xintela is conducting a first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, where three dose levels (4, 8 and 16 million stem cells) of the stem cell product XSTEM are being evaluated (8 patients/dose level). A total of 24 patients (41-75 years) with symptomatic moderate knee osteoarthritis (KL grade II-III) have received one injection of XSTEM into the knee joint. The primary goal of the study is to assess safety and tolerability of XSTEM. In addition, preliminary efficacy signals, such as reduced pain and improved joint function, as well as reduced degeneration of cartilage and other joint tissues, are being investigated every six months. An interim analysis of study data up to 18 months after treatment with X STEM, has now been performed. In summary, the results showed safety and sustained efficacy on pain, knee function and cartilage and bone structure. The major findings are described below: The study will be completed after the 24-month follow-up of the highest dose level of XSTEM and the final results are planned to be reported in September 2025. Patients at the lowest and mid dose levels have completed the study, 18 months after dosing. New Risk • Mar 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Negative equity (-kr5.9m). Earnings have declined by 0.8% per year over the past 5 years. Revenue is less than US$1m (kr4.2m revenue, or US$418k). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (kr266.3m market cap, or US$26.4m). New Risk • Aug 15
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr44m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-kr7.7m). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (85% increase in shares outstanding). Revenue is less than US$1m (kr377k revenue, or US$36k). Minor Risk Market cap is less than US$100m (kr202.5m market cap, or US$19.2m). New Risk • May 26
New major risk - Negative shareholders equity The company has negative equity. Total equity: -kr7.7m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr44m free cash flow). Negative equity (-kr7.7m). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Revenue is less than US$1m (kr377k revenue, or US$35k). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (kr154.2m market cap, or US$14.5m). Announcement • Feb 20
Xintela Appoints Lucienne Vonk as Chief Scientific Officer Xintela announces that Lucienne Vonk, previously Director Musculoskeletal Diseases at Xintela, has been appointed Chief Scientific Officer. She takes over the role from the CEO Evy Lundgren-Åkerlund. Lucienne Vonk has a strong background in cell-based therapies for cartilage regeneration, both in academic and industry settings. She obtained her PhD at the Academic Center for Dentistry Amsterdam (The Netherlands) investigating cartilage tissue engineering, after which she joined the department of Orthopaedics at the University Medical Center Utrecht (The Netherlands). There, her research focused on biological and cell-based therapies for cartilage regeneration, and she was part of a team that developed a one-stage cell-based treatment for focal articular cartilage defects. She also headed the Scientific Liaison department at CO.DON AG (Germany). She has held several positions on standing committees of the International Cartilage Regeneration and Joint Preservation Society (ICRS) and is senior associate editor for the Journal of Cartilage & Joint Preservation. Announcement • Dec 21
Xintela Publishes Efficacy Results with EQSTEM from Preclinical Equine OA Study Xintela AB (publ) announced that the results from Xintela's preclinical EQSTEM study in horses with post-traumatic osteoarthritis (OA) have been published in the scientific journal Cartilage. The results demonstrate less pain and less cartilage damage after treatment with the stem cell product EQSTEM, indicating a disease modifying effect of EQSTEM. Xintela has previously published that integrin a10b1-selected stem cells from horses, EQSTEM, which are the equivalent of the human stem cell product XSTEM®?, reduce cartilage and bone damage in a post-traumatic OA model in horses (Delco et al., Am J Sports Med. 2020;48:612). The study results that now have been published in the scientific Journal, further support a disease modifying effect of EQ STEM by Cartilage showing significantly less cartilage damage in treated horses compared to untreated horses. In addition, EQSTEM significantly reduced lameness in treated horses which indicates less pain and improved function of the treated joint. The results also demonstrated that specific biological factors were increased in the joint after injection of EQSTEM which provide further understanding of the mechanisms of action of EQSTEM. The study was conducted in collaboration with the University of Copenhagen. New Risk • Nov 24
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 77% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr69m free cash flow). Negative equity (-kr29m). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (kr135.4m market cap, or US$12.9m). Announcement • Oct 15
Xintela's Stem Cell Product, Xstem, Assessed as Safe At All Dose Levels in Knee Osteoarthritis Clinical Study Xintela's first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing three different dose levels of the stem cellproduct XSTEM®. The Safety Review Committee for the clinical study has now assessed all three dose levels safe at the planned three-month follow-up. XSTEM,which consists of allogeneic (donated) integrin 101-selected mesenchymal stem cells, is being developed and manufactured by Xintela. Patients with moderate knee osteoarthritis (grade II-III) have received one injection of XSTEM into the knee joint. Three different dose levels have so far been dosed in 24 patients (8 patients/dose level). The study enables an expansion of up to a total of 54 patients. Each patient is followed for 18 months with an efficacy reading every six months. The primary goal of the study is to show that XSTEM is safe. In addition, preliminary efficacy signals, such as reduced pain and improved joint function as well as reduced breakdown of joint cartilage and regeneration of damaged cartilage are being investigated. Announcement • Jun 23
Xintela Completes XSTEM Dosing at Third and Final Dose Level in Knee Osteoarthritis Clinical Study Xintela completed XSTEM dosing at third and final dose level in knee osteoarthritis clinical study. All patients on the third and final dose level have now been dosed in Xintela's first- in-human study (Phase I/IIa) for the treatment of knee osteoarthritis in Australia where three different dose levels of the stem cell product XSTEM® are being tested. The primary goal of the study is to show that XSTEM is safe but also to investigate preliminary efficacy signals. XSTEM, which consists of allogeneic (donated) integrin 101-selected mesenchymal stem cells, is developed and produced by Xintela. Patients with moderate knee osteoarthritis (grade II-III) receive one injection of XSTEM into the knee joint. Three different dose levels are being evaluated in a total of 24 patients with the possibility to increase the number up to 54 patients. The first two dose levels have been considered safe at the one month follow-up and all patients have now been dosed at the third and final dose level. Each patient will be followed for 18 months with efficacy readings every six months. The primary goal is to show that XSTEM is safe, but also investigate preliminary efficacy signals, such as reduced pain, reduced degradation of articular cartilage, regeneration of damaged cartilage and improved joint function. Xintela has previously reported that patients treated with the lowest dose of XSTEM, experience reduced pain and improved function of the knee after six months. Announcement • Jun 02
Xintela AB (publ) Announces Clinical Study with XSTEM for Knee Oeoarthritis Makes Good Progress Xintela AB (publ) is conducting a first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis in Australia where three different dose levels of the stem cell product XSTEM®? are being tested. The primary goal of the study is to show that XSTEM is safe but also to investigate preliminary efficacy signals. The treatment of 16 patients on the first and second dose levels with XSTEM has been assessed as safe at a one-month follow-up by the Safety Review Committee. The first efficacy results from the lowest dose show that patients experience reduced pain and improved joint function in the knee six months after the injection of XSTEM. XSTEM, which consists of allogeneic (donated) integrin a10b1-selected mesenchymal stem cells, is developed and produced by Xintela. Patients with moderate knee osteoarthritis (grades II-III) receive one injection of XSTEM into the knee joint. Three different dose levels are being evaluated in a total of 24 patients with the possibility to increase the number up to 54 patients. The first two dose levels have been considered safe and 6 out of 8 patients have been dosed at the third and final dose level. Xintela has now started to evaluate the first efficacy results for patients at the lowest dose level and can see an early trend showing that patients experience reduced pain and improve joint function in the knee six years after the injection with XSTEM. Each patient will be followed for 18 months with efficacy readings every six months. The primary goal is to show that X STEM is safe, but also to investigate preliminary efficacy signal, such as reduced pain, reduced degradation of articular cartilage, regeneration of damaged cartilage and improved joint function. Safety data from all dose levels and up to 12 months efficacy data from the lowest dose level are expected in 2023. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Lars Hedbys was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Lars Hedbys was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Jul 18
Chief Executive Officer recently bought kr116k worth of stock On the 14th of July, Evy Lundgren-Åkerlund bought around 50k shares on-market at roughly kr2.32 per share. This was the largest purchase by an insider in the last 3 months. This was Evy's only on-market trade for the last 12 months. Recent Insider Transactions • Jun 23
CFO & Finance Director recently bought kr51k worth of stock On the 21st of June, Gunnar Telhammar bought around 20k shares on-market at roughly kr2.54 per share. This was the largest purchase by an insider in the last 3 months. This was Gunnar's only on-market trade for the last 12 months. Is New 90 Day High Low • Mar 02
New 90-day low: kr2.96 The company is down 9.0% from its price of kr3.24 on 02 December 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. Reported Earnings • Feb 27
Full year 2020 earnings released: kr0.68 loss per share (vs kr1.10 loss in FY 2019) Full year 2020 results: Net loss: kr50.3m (loss widened 16% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Nov 05
New 90-day low: kr2.98 The company is down 38% from its price of kr4.83 on 06 August 2020. The Swedish market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. Is New 90 Day High Low • Oct 16
New 90-day low: kr3.78 The company is down 20% from its price of kr4.71 on 17 July 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. 
